Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | MEN1 | O00255 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | FABP3 | P05413 | 1/20 | 0.50 |
| ▸ | FABP4 | P15090 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | DHODH | Q02127 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | PTGES | O14684 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1284870 | 0.87 | ALDH1A1 (0.71) | KMT2AMEN1ALDH1A1FABP3FABP4 | |
| SCHEMBL28234137 | 0.83 | MEN1 (0.49) | KMT2AMEN1ALDH1A1RXFP1DHODH | |
| SCHEMBL30682029 | 0.83 | ALDH1A1 (0.50) | KMT2AMEN1ALDH1A1RXFP1DHODH | |
| SCHEMBL2310035 | 0.83 | ALDH1A1 (0.50) | KMT2AMEN1ALDH1A1RXFP1DHODH | |
| SCHEMBL6824035 | 0.80 | TSHR (0.71) | KMT2AMEN1ALDH1A1RXFP1HSD17B10 | |
| SCHEMBL790264 | 0.80 | PRNP (0.53) | KMT2AMEN1ALDH1A1RXFP1DHODH | |
| SCHEMBL2423281 | 0.80 | MEN1 (0.71) | KMT2AMEN1ALDH1A1RXFP1DHODH | |
| SCHEMBL28087640 | 0.80 | RXFP1 (0.53) | KMT2AMEN1ALDH1A1RXFP1DHODH | |
| SCHEMBL12386793 | 0.80 | RXFP1 (0.50) | KMT2AMEN1ALDH1A1RXFP1DHODH | |
| SCHEMBL790477 | 0.79 | PRNP (0.52) | KMT2AMEN1ALDH1A1RXFP1DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101384581-B | Benzoyl-piperidine derivatives as 5HT2/D3 modulators | HOFFMANN LA ROCHE | 2013-09-18 | — | — | CN | claimed |
| CN-101384581-A | Benzoyl-piperidine derivatives as 5HT2/D3 modulators | HOFFMANN LA ROCHE (CH) | 2009-03-11 | — | — | CN | claimed |
| CN-101384581-B | Benzoyl-piperidine derivatives as 5HT2/D3 modulators | HOFFMANN LA ROCHE | 2013-09-18 | — | — | CN | disclosed |
| US-8039490-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2011-10-18 | — | — | US | disclosed |
| CN-101384581-A | Benzoyl-piperidine derivatives as 5HT2/D3 modulators | HOFFMANN LA ROCHE (CH) | 2009-03-11 | — | — | CN | disclosed |
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-23 | — | — | US | disclosed |
| EP-0924209-B1 | Hypoglycemic imidazoline compounds | LILLY CO ELI (US) | 2003-05-02 | — | — | EP | disclosed |
| EP-1266897-A2 | Hypoglycemic imidazoline compounds | ELI LILLY AND COMPANY (US) | 2002-12-18 | — | — | EP | disclosed |
| CN-1117045-A | Substituted bicyclic heteroaroylguanidines, a process for their preparation, their use as a medicament or a diagnostic agent, and a medicament containing them | HOECHST AG (DE) | 1996-02-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197531-A1 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HTR2A, HTR3A, HTR2C | KMT2A 856/4885MEN1 3878/4885ALDH1A1 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.